CareDx’s AlloSeq cfDNA Awarded CE Mark ApprovalHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets open in 9 hrs 19 minsS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)CareDx’s AlloSeq cfDNA Awarded CE Mark ApprovalGlobeNewswireJanuary 10, 2020ReblogShareTweetShareCE mark approval enables global availability of dd-cfDNA measurement for monitoring transplant healthSOUTH SAN FRANCISCO, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced that it has received CE mark approval for its AlloSeq cfDNA kit, making it broadly available to transplant patients and clinicians.AlloSeq cfDNA is an innovative kit based solution, run on next generation sequencing (NGS) platforms, that enables measurement of dd-cfDNA in labs outside of the US. CareDx launched AlloSeq cfDNA during the European Society for Organ Transplantation (ESOT) Congress.“AlloSeq cfDNA provides a measure of organ injury that can help monitor transplant patient outcomes. With the CE mark, we can begin our pan-European dd-cfDNA registry and studies with CareDx,” said Dr. Phil Mason, Transplant Nephrologist, Oxford.“Implementing AlloSeq cfDNA in my laboratory was easy, and with minimum training my staff was able to precisely measuring donor-derived cfDNA in our transplant recipient samples,” said Jean Villard, MD, PhD, Geneva University Hospital.“Transplantation is global, and CareDx is committed to providing best-in-class solutions for all transplant patients,” said Peter Maag, CEO at CareDx. “We are excited to announce this milestone of broad commercialization of AlloSeq cfDNA.”About CareDxCareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers products, testing services and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients.For more information, please visit: www.CareDx.comCONTACTS:Sasha King Chief Marketing Officer, CareDx Inc. 415-287-2393 sking@caredx.comInvestor RelationsGreg Chodaczek 646-924-1769 investor@caredx.comReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance Video'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoMost face masks won’t protect you from the coronavirusYahoo FinanceStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinanceWhat the GM strike means for the U.S. economyYahoo FinanceBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'Yahoo FinanceWhat to watch in the markets: Friday, February 28Yahoo Finance VideoAurora Cannabis tumbles after double downgradeYahoo Finance Video